Ambrosia Biosciences secured $100 million in an oversubscribed Series B round to advance an oral small-molecule GLP-1 candidate aimed at competing in the new oral obesity drug landscape. The Denver-area company said the funding will support clinical development of its lead program and other cardiometabolic pipeline assets. The round was co-led by Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital, according to the report. Ambrosia positions its approach around combinability and convenience versus weekly injectable GLP-1s, following regulatory momentum that broadened oral obesity options. With competitors and peers also racing toward oral incretin-based therapies, the financing underscores how investor focus is shifting beyond injections—toward next-wave formulations that can drive access and adherence at scale.